MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3: a randomized, double-blind, sham-controlled trial

R. Maas, S. Teerenstra, I. Toni, T. Klockgether, D. Schutter, B. Vande Warrenburg (Nijmegen, Netherlands)

Meeting: 2022 International Congress

Abstract Number: 452

Keywords: Ataxia: Treatment, Neurostimulation, Spinocerebellar ataxia

Category: Ataxia

Objective: To investigate if a 2-week regimen comprising daily sessions of cerebellar anodal transcranial direct current stimulation (tDCS) 1) diminishes ataxia and non-motor symptom severity and 2) alters cerebellar-motor cortex (M1) connectivity in individuals with spinocerebellar ataxia type 3 (SCA3).

Background: Repeated sessions of cerebellar tDCS have been suggested to modulate cerebellar-M1 connectivity and decrease ataxia severity. However, therapeutic trials involving etiologically homogeneous groups of ataxia patients are lacking.

Method: We conducted a randomized, double-blind, sham-controlled trial in which 20 mildly to moderately affected SCA3 patients received 10 sessions of real or sham cerebellar tDCS (i.e., 5 days per week for 2 consecutive weeks). Effects were evaluated after 2 weeks, 3 months, 6 months, and 12 months. Change in Scale for the Assessment and Rating of Ataxia (SARA) score after 2 weeks was defined as the primary endpoint. Static posturography, SCA Functional Index tests, various patient-reported outcome measures, the cerebellar cognitive affective syndrome scale, and paired-pulse transcranial magnetic stimulation to examine cerebellar brain inhibition (CBI) served as secondary endpoints.

Results: Absolute change in SARA score did not differ between both trial arms at any of the time points. We observed significant short-term improvements in several motor, cognitive, and patient-reported outcomes after the last stimulation session in both groups but no treatment effects in favor of real tDCS. Nonetheless, some of the patients in the intervention arm showed a sustained reduction in SARA score lasting 6 or even 12 months, indicating interindividual variability in treatment response. CBI, which reflects the functional integrity of the cerebellothalamocortical tract, remained unchanged after 10 tDCS sessions. Albeit exploratory, there was some indication for a decrease in SARA speech score after 6 and 12 months and in the number of extracerebellar signs after 3 and 6 months.

Conclusion: This study does not provide evidence that a 2-week treatment with daily cerebellar tDCS sessions reduces ataxia severity or restores cerebellar-M1 connectivity in early-to-middle-stage SCA3 patients at the group level. In order to potentially increase therapeutic efficacy, further research is warranted to identify individual predictors of symptomatic improvement.

To cite this abstract in AMA style:

R. Maas, S. Teerenstra, I. Toni, T. Klockgether, D. Schutter, B. Vande Warrenburg. Cerebellar transcranial direct current stimulation in spinocerebellar ataxia type 3: a randomized, double-blind, sham-controlled trial [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/cerebellar-transcranial-direct-current-stimulation-in-spinocerebellar-ataxia-type-3-a-randomized-double-blind-sham-controlled-trial/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/cerebellar-transcranial-direct-current-stimulation-in-spinocerebellar-ataxia-type-3-a-randomized-double-blind-sham-controlled-trial/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley